CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CFO Scott Blumberg sold 990 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $25.00, for a total transaction of $24,750.00. Following the completion of the sale, the chief financial officer directly owned 148,121 shares in the company, valued at approximately $3,703,025. This represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Scott Blumberg also recently made the following trade(s):
- On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36.
CeriBell Trading Down 2.3%
CBLL stock traded down $0.58 during midday trading on Thursday, hitting $24.31. The stock had a trading volume of 262,277 shares, compared to its average volume of 469,652. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average price of $19.43 and a two-hundred day moving average price of $19.19. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The firm has a market cap of $933.02 million, a P/E ratio of -13.81 and a beta of 0.81.
Institutional Investors Weigh In On CeriBell
A number of hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after purchasing an additional 374,179 shares during the period. Rhumbline Advisers lifted its stake in shares of CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after buying an additional 17,177 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after buying an additional 5,200 shares during the last quarter. Quantbot Technologies LP increased its position in shares of CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after acquiring an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of CeriBell during the second quarter worth about $197,000.
Wall Street Analyst Weigh In
Several analysts have recently commented on CBLL shares. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Canaccord Genuity Group raised their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, BTIG Research lifted their price target on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.
Get Our Latest Report on CeriBell
CeriBell Company Profile
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Stories
- Five stocks we like better than CeriBell
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
